Sacramento Bee3d
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
"We are fully committed to bringing this breakthrough drug to patients as quickly as possible while backing everything we do ...
greenmarketreport1d
MIRA says ketamine-based drug beats current pain treatments in study
The firm says it could offer an alternative to existing treatments while sidestepping addiction concerns that have plagued ...
bovnews1d
Why Did Mira Pharmaceuticals Inc (MIRA) Plummet? Key Factors Explained
In terms of valuation, Mira Pharmaceuticals Inc’s market capitalization stands at $15.52 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...
MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments
MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...
Zacks Small Cap Research on MSN2d
MIRA Continues to Post Outstanding Test Results
MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...
Yahoo Finance2d
MIRA Continues to Post Outstanding Test Results
MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment ...
Kansas City Star2d
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com. This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related ...